1. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
- Author
-
Massimo, Fabiani, Maria, Puopolo, Cristina, Morciano, Matteo, Spuri, Stefania, Spila Alegiani, Antonietta, Filia, Fortunato, D'Ancona, Martina, Del Manso, Flavia, Riccardo, Marco, Tallon, Valeria, Proietti, Chiara, Sacco, Marco, Massari, Roberto, Da Cas, Alberto, Mateo-Urdiales, Andrea, Siddu, Serena, Battilomo, Antonino, Bella, Anna Teresa, Palamara, Patrizia, Popoli, Silvio, Brusaferro, Giovanni, Rezza, Francesca, Menniti Ippolito, Patrizio, Pezzotti, and Nadia, Raccanello
- Subjects
Adult ,Male ,Secondary ,Time Factors ,Adolescent ,Immunization, Secondary ,Severity of Illness Index ,Young Adult ,Immunogenicity, Vaccine ,80 and over ,Humans ,BNT162 Vaccine ,Aged ,Aged, 80 and over ,SARS-CoV-2 ,Incidence ,Vaccination ,COVID-19 ,General Medicine ,Middle Aged ,Immunogenicity ,Treatment Outcome ,2019-nCoV Vaccine mRNA-1273 ,Female ,Follow-Up Studies ,Italy ,Immunization ,Vaccine - Abstract
ObjectivesTo estimate the effectiveness of mRNA vaccines against SARS-CoV-2 infection and severe covid-19 at different time after vaccination.DesignRetrospective cohort study.SettingItaly, 27 December 2020 to 7 November 2021.Participants33 250 344 people aged ≥16 years who received a first dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine and did not have a previous diagnosis of SARS-CoV-2 infection.Main outcome measuresSARS-CoV-2 infection and severe covid-19 (admission to hospital or death). Data were divided by weekly time intervals after vaccination. Incidence rate ratios at different time intervals were estimated by multilevel negative binomial models with robust variance estimator. Sex, age group, brand of vaccine, priority risk category, and regional weekly incidence in the general population were included as covariates. Geographic region was included as a random effect. Adjusted vaccine effectiveness was calculated as (1−IRR)×100, where IRR=incidence rate ratio, with the time interval 0-14 days after the first dose of vaccine as the reference.ResultsDuring the epidemic phase when the delta variant was the predominant strain of the SARS-CoV-2 virus, vaccine effectiveness against SARS-CoV-2 infection significantly decreased (PConclusionsThe results support the vaccination campaigns targeting high risk people, those aged ≥60 years, and healthcare workers to receive a booster dose of vaccine six months after the primary vaccination cycle. The results also suggest that timing the booster dose earlier than six months after the primary vaccination cycle and extending the offer of the booster dose to the wider eligible population might be warranted.
- Published
- 2022